Sharif Welcomes Trump’s Ceasefire Extension in U.S.-Israel-Iran Conflict 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Mexico Senate Seeks Answers on Deadly Chihuahua Crash Involving U.S. and Mexican Officials 
Victoria's Free Public Transport Extension Eases Cost-of-Living Pressure Amid Global Fuel Crisis 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Trump Administration Proposes New Rule to Limit Joint Employer Liability 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
US Sanctions Target Iran Weapons Network Amid Rising Tensions 
DHS Shutdown Delays World Cup Security Planning Despite Full Funding Release 
U.S. Intercepts Iranian Oil Tankers in Asian Waters Amid Rising Global Energy Crisis 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
New Zealand Labour Backs India Free Trade Deal, Boosting Chances of Parliamentary Approval 
Trump Administration Files Fraud Charges Against Southern Poverty Law Center Over Informant Payments 
Why the future of marijuana legalization remains hazy despite high public support 
Senate Republicans Push $70B Immigration Funding Plan Amid DHS Shutdown Standoff 
U.S. Health Secretary Robert F. Kennedy Jr. told lawmakers this week that he is open to sharing details about David Geier’s contract with the Department of Health and Human Services (HHS), signaling growing scrutiny over the controversial appointment. During a Senate Finance Committee hearing, Kennedy stated that the contract could be provided to senators before the end of the week, offering what may become the first clear explanation of Geier’s responsibilities within the agency.
David Geier, known for his long-standing anti-vaccine activism, is currently working as a contractor tied to the Centers for Disease Control and Prevention (CDC). According to federal records, he is listed as a senior data analyst within the HHS system. His involvement has raised concerns among lawmakers and public health experts, particularly given his history of promoting debunked claims linking vaccines to autism.
Senator Ben Ray Luján of New Mexico pressed Kennedy on whether the administration would also release the protocols guiding Geier’s work. Kennedy responded that such protocols are not yet in place but promised they would be shared once the vaccine safety review is completed. Kennedy has previously indicated that Geier is leading a review of CDC vaccine data, a move that has sparked debate due to Geier’s controversial background.
Geier’s past actions have added to the concern. He was previously fined in Maryland for practicing medicine without a license and for administering unsafe treatments to children with autism. Critics argue that his involvement in federal health initiatives could undermine public trust in vaccine safety.
The situation highlights ongoing tensions around vaccine policy, public health transparency, and the role of individuals with disputed scientific views in government positions. As pressure builds, the release of Geier’s HHS contract could play a key role in shaping public and political response to the administration’s handling of vaccine-related issues.
